1. Electrochemotherapy with bleomycin : The first clinical experience in malignant melanoma patientsZvonimir Rudolf, Borut Štabuc, Maja Čemažar, Damijan Miklavčič, Lojze Vodovnik, Gregor Serša, 1995, original scientific article Keywords: melanoma therapy, bleomycin, electric stimulation therapy Published in DiRROS: 15.01.2024; Views: 133; Downloads: 37 Full text (418,42 KB) |
2. Elektrokemoterapija malignega melanomaGregor Serša, Borut Štabuc, Tanja Čufer, Boris Jančar, Damijan Miklavčič, Maja Čemažar, Zvonimir Rudolf, 1999, published scientific conference contribution Keywords: melanom, zdravljenje, bleomicin, cisplatin, električna stimulacija, elektrokemoterapija, elektroporacija, melanoma therapy, bleomycin, cisplatin, electric stimulation therapy, electrochemotherapy, electroporation Published in DiRROS: 27.11.2023; Views: 166; Downloads: 57 Full text (617,96 KB) |
3. Bleomycin concentration in patientsʹ plasma and tumors after electrochemotherapy : a study from InspECT GroupAleš Grošelj, Maša Omerzel, Mojca Kržan, Tina Kosjek, Krisztina Bottyán, Helena Plešnik, Črt Jamšek, Maja Čemažar, Erika Kis, Gregor Serša, 2021, original scientific article Keywords: electrochemotherapy, electroporation, bleomycin Published in DiRROS: 10.10.2022; Views: 468; Downloads: 227 Full text (670,54 KB) This document has many files! More... |
4. Biological factors of the tumour response to electrochemotherapy : review of the evidence and a research roadmapGregor Serša, Katja Uršič Valentinuzzi, Maja Čemažar, Richard Heller, Maša Omerzel, Luca Giovanni Campana, 2021, review article Abstract: The beneficial effects of electrochemotherapy (ECT) for superficial tumours and, more recently, deepseated malignancies in terms of local control and quality of life are widely accepted. However, the variability in responses across histotypes needs to be explored. Currently, patient selection for ECT is based on clinical factors (tumour size, histotype, and exposure to previous oncological treatments), whereas there are no biomarkers to predict the response to treatment. In this field, two major areas of investigation can be identified, i.e., tumour cell characteristics and the tumour microenvironment (vasculature, extracellular matrix, and immune infiltrate). For each of these areas, we describe the current knowledge and discuss how to foster further investigation. This review aims to provide a summary of the currently used guiding clinical factors and delineates a research roadmap for future studies to identify putative biomarkers of response to ECT. These biomarkers may allow researchers to improve ECT practice by customising treatment parameters, manipulating the tumour and its microenvironment, and exploring novel therapeutic combinations. Keywords: biological factors, biomarkers, electrochemotherapy, bleomycin, cisplatin Published in DiRROS: 23.09.2022; Views: 502; Downloads: 151 Full text (1,32 MB) |
5. PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in miceMaša Omerzel, Tanja Jesenko, Boštjan Markelc, Larisa Janžič, Maja Čemažar, Gregor Serša, 2021, original scientific article Abstract: Electrochemotherapy (ECT), a local therapy, has different effectiveness among tumor types. In breast can-cer, its effectiveness is low; therefore, combined therapies are needed. The aim of our study was to com-bine ECT with PARP inhibitor olaparib, which could inhibit the repair of bleomycin or cisplatin inducedDNA damage and potentiate the effectiveness of ECT. The effects of combined therapy were studied inBRCA1mutated (HCC1937) and non-mutated (HCC1143) triple negative breast cancer cell lines.Therapeutic effectiveness was studied in 2D and 3D cell cultures andin vivoon subcutaneousHCC1937 tumor model in mice. The underlying mechanism of combined therapy was determined withthe evaluation ofcH2AX foci. Combined therapy of ECT with bleomycin and olaparib potentiated theeffectiveness of ECT inBRCA1mutated HCC1937, but not in non-mutated HCC1143 cells. The combinedtherapy had a synergistic effect, which was due to the increased number of DNA double strand breaks.Addition of olaparib to ECT with bleomycinin vivoin HCC1937 tumor model had only minimal effect,indicating repetitive olaparib treatment would be needed. This study demonstrates that DNA repar inhibiting drugs, like olaparib, have the potential to increase the effectiveness of ECT with bleomycin. Keywords: electrochemotherapy, breast cancer, olaparib, bleomycin Published in DiRROS: 21.09.2022; Views: 495; Downloads: 171 Full text (3,74 MB) |